EN DE
Watch LifeMD Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LifeMD Inc (LFMD) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of LifeMD Inc stock $2.05, price $1.85, upside +10.8%, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US53216B1044

LI LifeMD Inc logo Thin data Nov 15, 2026

LifeMD Inc

LFMD · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value $2.05 · Fairly valued 
Expensive Growth (revenue 5y +39.1 %/yr in USD) 
Thin margins · 0.1% net margin (TTM) 
Quality 32/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (3/10) 
Narrow moat 16/100 · thin data
Thin data 
Estimate
Watch LifeMD Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.06 $1.15 Fair Value $2.05 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $1.15 – $15.06 · fair‑value band $1.54 – $2.57 · the $1.85 price screens below the $2.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow LifeMD in your weekly email

Every Wednesday you see whether LifeMD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States.

Show moreShow less

It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss.

The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more.

In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

Stock analysis

LifeMD Inc (LFMD) currently trades at $1.85, while our estimate is $2.05, so the stock looks roughly fairly valued today (gap 9.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.54 (bear) to $2.57 (bull), the price of $1.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

LifeMD Inc reported revenue of $194M in FY2025 versus $92.9M in FY2021, a compound +20.2%/yr. Reported net income was −$7.1M in FY2025.

Key figures

Market cap $89.2M Micro · P/S ratio 0.56 · EPS (TTM) $−0.5200 · Dividend yield 2.9% · Net margin −3.7% · Return on equity −1,493% · Return on assets (EBIT) −67.2% (5-year average) · Operating margin −11.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 11%, LFMD screens cheaper than that median.

Fair Value

Bear $1.54 Fair Value $2.05 Bull $2.57
Price $1.85 · Upside +10.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 42
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 11
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleJessica FriedemanChief Marketing Officer15,000 shares at $3.61$54,150Dec 9, 2025

Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.1%
Start year 2020 (pandemic). Over 10 years: +66.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−155.0% (2020) → −4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LFMD, get fair value alerts →

Compare LifeMD Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 140 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside +10.8% · Above median
Profitability
Return on assets −10.1% · Below median
Net margin (12 months) 0.1% · Below median
Operating margin (12 months) −11.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) −6.5% · Bottom 25%
Dividend yield (12 months) 2.9% · Above median
Balance sheet
Debt / equity 0.43× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 3.85× · Pricier than median
P/S (12 months) 0.47× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)48 · sector 15
FUTURE (revenue growth)0 · sector 46
PAST (return on equity)0 · sector 3
HEALTH (low debt)79 · sector 98
DIVIDEND (yield)59 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.77 $36.67 +12% vs LFMD
Veeva Systems Inc VEEV $299.28 $329.21 +10% vs LFMD
HealthEquity, Inc HQY $104.58 $115.04 +10% vs LFMD
Waystar Holding WAY $28.11 $29.10 +4% vs LFMD
Tempus AI, Inc TEM $64.76 $52.58 −19% vs LFMD
HeartFlow, Inc HTFL $46.86 $30.50 −35% vs LFMD
Hinge Health, Inc HNGE $121.29 $51.25 −58% vs LFMD
Pro Medicus Limited PME A$201.65 A$82.80 −59% vs LFMD
BrightSpring Health Services, Inc BTSG $71.37 $25.72 −64% vs LFMD
XtalPi Holdings 2228 HK$5.53 HK$1.53 −72% vs LFMD

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LifeMD Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LifeMD Inc Fair Value". https://www.fairvalue-calculator.com/stock/LFMD

Frequently asked questions

Is LifeMD Inc (LFMD) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $2.05 versus a price of $1.85, about +11% upside (fairly valued).
What is the fair value of LFMD?
Our estimate for LifeMD Inc is $2.05 (as of Nov 15, 2026), built from audited fundamentals. The current price: $1.85.
What is the quality score of LFMD?
LifeMD Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LifeMD Inc (LFMD)?
Our calculated price target is the estimate of $2.05 (as of Nov 15, 2026). Cautious scenario $1.54, optimistic scenario $2.57. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the LifeMD Inc stock forecast for 2026?
Our estimate puts fair value at $2.05, about +11% upside versus a price of $1.85 (fairly valued). Cautious scenario $1.54, optimistic scenario $2.57. The calculation is refreshed regularly with new filings.
What is the revenue of LifeMD Inc (LFMD)?
LifeMD Inc reported trailing-twelve-month revenue of about $189M (latest available figure, as of Nov 15, 2026).
Does LifeMD Inc pay a dividend?
LifeMD Inc currently shows a dividend yield of 2.93% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of LifeMD Inc (LFMD)?
LifeMD Inc has a dividend yield of 2.9%.
What is the intrinsic value of LifeMD Inc (LFMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LifeMD Inc it is $2.05 per share (as of Nov 15, 2026), against a price of $1.85.
Is LifeMD Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, LFMD trades below its calculated fair value: price $1.85, fair value $2.05, a gap of about +11% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LFMD?
No. The price is what the market pays today ($1.85); the fair value is what the company's own numbers justify ($2.05). For LifeMD Inc the two are $0.2000 per share apart. That gap is exactly why we show both numbers side by side.
How much is LifeMD Inc worth?
The market values LifeMD Inc at about $89.2M (market capitalisation, as of Nov 15, 2026). Per share that is $1.85; our models calculate a fair value of $2.05 per share.
What do the bullish and bearish scenarios say about LFMD?
Our models span a range for LifeMD Inc: cautious scenario $1.54, base $2.05, optimistic $2.57 per share (as of Nov 15, 2026, price $1.85). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LifeMD Inc (LFMD)?
Balance-sheet figures for LifeMD Inc (as of Nov 15, 2026): debt of 0.43 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is LFMD from its 52-week high?
LifeMD Inc trades at $1.85, about 65% below its 52-week high of $5.27 and 12% above the low of $1.66 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $2.05 is for.
Which stocks are comparable to LifeMD Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LifeMD Inc stock attractive at the current price?
The data as of Nov 15, 2026: price $1.85, calculated fair value $2.05 (+11%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. LifeMD Inc currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LifeMD Inc (LFMD)?
The closing price on Nov 16, 2026 was $1.85. Our estimate is $2.05, about +11% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LifeMD Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of LifeMD Inc

How large is the market capitalisation of LifeMD Inc (LFMD)?
The market capitalisation of LifeMD Inc is $89.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LifeMD Inc (LFMD)?
The price-to-sales ratio of LifeMD Inc is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LifeMD Inc (LFMD)?
Earnings per share at LifeMD Inc are $−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of LifeMD Inc (LFMD)?
The dividend yield of LifeMD Inc is 2.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of LifeMD Inc (LFMD)?
The net margin of LifeMD Inc is −3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LifeMD Inc (LFMD)?
The return on equity (ROE) of LifeMD Inc is −1,493% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LifeMD Inc (LFMD)?
On an EBIT basis the return on assets of LifeMD Inc is −67.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LifeMD Inc (LFMD)?
The operating margin of LifeMD Inc is −11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LifeMD Inc (LFMD)?
Revenue at LifeMD Inc is down 6.5% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LifeMD Inc (LFMD) generate?
The free cash flow of LifeMD Inc is −$1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LifeMD Inc (LFMD) hold?
LifeMD Inc holds more cash than debt, $30.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch LifeMD Inc in the live analysis

One click puts LifeMD Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.